Opinions
James Hodgins
Tribute Pharmaceuticals Canada Inc
ARZ-T
DON'T BUY
May 26, 2015
$1.290
Stock price when the opinion was issued
Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
COMMENT
There are a whole bunch of small pharmaceutical companies that are just kind of getting started right now. What this company is doing so far is good. To grow in this world right now, because the acquisition world is so hot, it is hard to find stuff. What you have to do now is get product rights and slowly develop them over time. His guess on this one is that this will be a good, long term holding, but there might be more interesting places to be in the short term. (See Top Picks.)
Pharma & Healthcare
Quite expensive at about 13X EBITDA. He would much prefer Merus (MSL-T) than this.